Evidence map›Paper›PMID 34776479›Full record

ArticleInternal medicine (Tokyo, Japan)2022

Pembrolizumab-related Immune Thrombocytopenia in a Patient with Lung Adenocarcinoma Treated by Radiotherapy: Potential Immune-related Adverse Event Elicited by Radiation Therapy.

Daisuke Tamanoi, Koichi Saruwatari, Kosuke Imamura, Ryo Sato, Takuya Jodai, Shohei Hamada, Yusuke Tomita, Sho Saeki, Shikiko Ueno, Yuji Yonemura and 2 more

Open access · diamondAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Internal medicine (Tokyo, Japan), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.4field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 5 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 1 institution in 1 country.

Daisuke TamanoiDepartment of Respiratory Medicine, Kumamoto University Hospital, Japan.
Koichi SaruwatariDepartment of Respiratory Medicine, Kumamoto University Hospital, Japan.
Kosuke ImamuraDepartment of Respiratory Medicine, Kumamoto University Hospital, Japan.
Ryo SatoDepartment of Respiratory Medicine, Kumamoto University Hospital, Japan.
Takuya JodaiDepartment of Respiratory Medicine, Kumamoto University Hospital, Japan.
Shohei HamadaDepartment of Respiratory Medicine, Kumamoto University Hospital, Japan.
Yusuke TomitaDepartment of Respiratory Medicine, Kumamoto University Hospital, Japan.
Sho SaekiDepartment of Respiratory Medicine, Kumamoto University Hospital, Japan.
Shikiko UenoDepartment of Hematology, Rheumatology and Infectious Disease, Kumamoto University Hospital, Japan.
Yuji YonemuraDepartment of Transfusion Medicine and Cell Therapy, Kumamoto University Hospital, Japan.
Hidenori IchiyasuDepartment of Respiratory Medicine, Kumamoto University Hospital, Japan.
Takuro SakagamiDepartment of Respiratory Medicine, Kumamoto University Hospital, Japan.
Kumamoto University Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The effect of radiotherapy during immunotherapy on immune-related adverse events (irAEs) is not fully understood. We herein report a 74-year-old woman diagnosed with lung adenocarcinoma with programmed death ligand 1 expression ≥50% and treated with pembrolizumab. She developed fatal immune thrombocytopenia associated with pembrolizumab immediately following radiotherapy. A flow cytometry analysis of peripheral blood detected an increased expression of programmed death-1 (PD-1) and Ki-67 in CD4

Indexed as

Adenocarcinoma of LungAntineoplastic Agents, ImmunologicalLung NeoplasmsPurpura, Thrombocytopenic, IdiopathicThrombocytopeniaAgedAntibodies, Monoclonal, HumanizedCD8-Positive T-LymphocytesFemaleHumansAntibodies, Monoclonal, HumanizedAntineoplastic Agents, Immunologicalpembrolizumabimmune-related adverse effectsimmunotherapynon-small-cell lung cancerPD-1stereotactic radiotherapy

Identifiers

PMID34776479
PMCPMC9259326
OpenAlexW3214275816

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.